Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epidermal growth factor cancer vaccine - Bioven

Next Previous
X
Search
Drug Profile

Epidermal growth factor cancer vaccine - Bioven

Alternative Names: BV NSCLC 001; BV NSCLC 002; BVN-NSCLC-002; Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine; Center of Molecular Immunology Epidermal Growth Factor Vaccine; CimaVax EGF; CIMAvax Epidermal Growth Factor Vaccine; CIMAvax IM; CIMAvax-EGF; EGF cancer vaccine; EGF-P64K cancer vaccine; EGF-PTI; hrEGF-rP64k-Montanide ISA 51 VG; Recombinant human EGF-P64K/montanide Vaccine; Recombinant human EGF-rP64K/montanide ISA 51 vaccine; rEGF-P64K/Montanide ISA 51 vaccine; SAI-EGF

Latest Information Update: 04 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Bioven; Center of Molecular Immunology; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Prostate cancer
  • Discontinued Colorectal cancer; Gastric cancer

Most Recent Events

  • 04 Jan 2024 No development reported - Phase-III for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Bulgaria (IM)
  • 04 Jan 2024 No development reported - Phase-III for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Georgia (IM)
  • 04 Jan 2024 No development reported - Phase-III for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Romania (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top